Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system?

Research output: Contribution to journalReview article

5 Scopus citations


Cardiovascular mortality and hypertension remain common in the dialysis population, and two recent meta-analyses have suggested that antihypertensive pharmacotherapy reduces cardiovascular events in dialysis patients. Based on their benefits in other populations, blockers of the renin-angiotensin- aldosterone system (RAAS) are an attractive treatment option. The evidence that RAAS blockers improve surrogate end points is mixed. However, a recent meta-analysis found significant improvement in left ventricular mass with RAAS-blocking drugs in hemodialysis patients. Only a few trials have examined RAAS-blocking drugs and cardiovascular events in dialysis patients, and a recent meta-analysis found no significant benefit in hemodialysis patients. The single trial of peritoneal dialysis patients that reported cardiovascular events found no benefit from RAAS blockers. Fortunately, the risk of hyperkalemia appears low. Based on the available evidence, we cannot categorically recommend that all hypertensive dialysis patients be treated with RAAS blockers. We await the results of adequately powered clinical trials.

Original languageEnglish (US)
Pages (from-to)356-363
Number of pages8
JournalCurrent hypertension reports
Issue number5
StatePublished - Oct 1 2010
Externally publishedYes


  • ACE inhibitor
  • ARB
  • Blood pressure
  • Cardiovascular events
  • ESRD
  • End-stage renal disease
  • Hemodialysis
  • Hypertension
  • Kidney
  • Mortality
  • Myocardial infarction
  • Peritoneal dialysis
  • RAAS
  • Renin-angiotensin system
  • Residual renal function
  • Stroke
  • Treatment

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Should all hypertensive dialysis patients receive a blocker of the renin-angiotensin system?'. Together they form a unique fingerprint.

  • Cite this